Thursday, March 28, 2024

Creating liberating content

Oracle Corp’s (NYSE: ORCL)...

Oracle Corp (NYSE: ORCL) falls down to its knees, share dropped over 12.15%...

RTX Corp (NYSE: RTX)...

RTX Corp (NYSE: RTX) experienced a notable decline of -7.22%, amounting to $6.03...

GameStop Corp. (NYSE:GME) Quarter...

GameStop Corp. (NYSE: GME) to announce its second quarter fiscal 2023 results after...

Advanced Micro Devices (NASDAQ:AMD)...

Shares of Advanced Micro Devices (NASDAQ:AMD) drops 0.38% in afterhours in last trading...
HomeBiotech-PharmaKiromic BioPharma, Inc....

Kiromic BioPharma, Inc. (NASDAQ: KRBP) Receives FDA Validating Written Input on Its DeltacelTM Development Strategy

A clinical-stage fully-integrated biotherapeutics company, Kiromic BioPharma, Inc. (NASDAQ: KRBP) plunged over 15.88% in early trading session on Friday as It announces that the FDA provided validating written input on its DeltacelTM development strategy on October 4, 2022, in response to its Type B Pre-IND meeting request.

The purpose of the Pre-IND meeting request was to seek alignment with and obtain FDA guidance on Kiromic’s proposed development strategy for Deltacel /KB-GDT for treating subjects with Non-Small Cell Lung Cancer, including chemistry, manufacturing, and controls (CMC), nonclinical studies, and clinical study plan (NSCLC). Kiromic will incorporate the FDA Pre-IND written confirmatory input and suggestions into a comprehensive IND filing package for a clinical study scheduled to begin in Q1 2023.

Chief Executive Officer of Kiromic, Pietro Bersani stated that they are pleased to have received such positive FDA input on DeltacelTM/KB-GDT, validating their development plan for this therapeutic candidate. It was a strategic decision to focus on metastatic stage 4 lung cancers as their initial indication in treating solid malignancies, and they are extremely encouraged to be able to continue their goal to target solid malignancies, which account for more than 90% of all cancers.

To reinforce Management’s commitment to executing the Deltacel-aligned development plan, the Company has simplified its operations and aligned key resources to advance its DeltacelTM product candidate while preserving its other product candidates, ProcelTM and IsocelTM. Kiromic’s management took the painful but necessary choice to remove 20 roles, or around 29% of its personnel, as part of that aligned plan and following a comprehensive examination to enhance operational savings. The Company believes that these major measures and overall strategy are consistent with the funding options it is actively exploring.

Oracle Corp’s (NYSE: ORCL) Cloud Business Faces Headwinds: What Lies Ahead

Oracle Corp (NYSE: ORCL) falls down to its knees, share dropped over 12.15% or $15.21 to trade at $111.50 in pre trading session on...

RTX Corp (NYSE: RTX) Updates 2023-2025 Outlook amid Engine Part Challenge

RTX Corp (NYSE: RTX) experienced a notable decline of -7.22%, amounting to $6.03 per share, bringing its current trading price to $77.45. The company,...

GameStop Corp. (NYSE:GME) Quarter Report: Resilience amidst Market Turbulence

GameStop Corp. (NYSE: GME) to announce its second quarter fiscal 2023 results after the market closes today. Shares were slightly down in the pre-trading...

Continue reading

Alphabet Inc. (NASDAQ: GOOGL) In Talks to Reduce European IT Jobs After ‘Disastrous’ Layoffs

Shares of Alphabet Inc. (NASDAQ: GOOGL) inches down in pre session on Thursday after big American IT businesses are suddenly discovering how hard it is to decrease personnel in Europe after announcing the greatest rounds of layoffs in their...

Apple Inc. (NASDAQ: AAPL) Unveils Appearance of Its First Retail Location in India

Shares of Apple Inc. (NASDAQ: AAPL) inches down in afterhours trading as many people rushed to get a glance of the store's black and yellow artwork, which was modeled after Mumbai's famous cabs, as the company unveiled the appearance...

Credit Suisse (NYSE: CS) and UBS Group AG (NYSE: UBS) In Flux after Probe into Credit Suisse Acquisition

Credit Suisse (NYSE: CS) and UBS Group AG (NYSE: UBS) shares revamp its position on Tuesday from previous session following the emergency merger of the two lenders was the subject of an inquiry by Switzerland's federal prosecutor. The prosecutor has...

Enjoy exclusive access to all of our content

Get an online subscription and you can unlock any article you come across.